Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

Strauss, Gary M.; Herndon, Joel; Maddaus, Michael A.; Johnstone, David; Johnson, Eric A.; Watson, Dorothy; Sugarbaker, David J.; Schilsky, Richard L.; Green, M. R.

doi:10.1200/jco.2004.22.90140.7019

Cited by 127 publications

(133 citation statements)

References 0 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…1 The results of 2 randomized trials to assess the benefit of adjuvant chemotherapy in patients with early-stage NSCLC were reported at the 40th Annual Meeting of the American Society of Clinical Oncology. 3,4 Furthermore, a recent large scale randomized clinical trial launched just after the publication of the meta-analysis concluded that patients assigned to CDDP-based postoperative adjuvant chemotherapy had a statistically significantly higher survival rate than those assigned to postoperative observation (44.5% vs. 40.4% at 5 years; p < 0.03). 2 Even though a statistically significant difference was found in this study, 5-year-survival rate benefit was approximately 5-15%.…”

Section: Discussionmentioning

confidence: 99%

“…1 In 2004 reports demonstrated the benefit of postoperative adjuvant chemotherapy. [2][3][4] The indication of postoperative chemotherapy is no longer considered controversial. We reported recently that postoperative adjuvant chemotherapy with oral UFT (DPD Inhibitory Fluoropyrimidine, Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) provided better survival than surgical treatment alone in patients with Stage I adenocarcinoma of the lung.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Identification of postoperative adjuvant chemotherapy responders in non‐small cell lung cancer by novel biomarker

Hirano

Kato

Maeda

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Cisplatin-based (CDDP-based) adjuvant chemotherapy of nonsmall cell lung cancer (NSCLC) was reported to yield 5-15% improvement in 5-year survival compared to complete resection alone. The importance of information concerning preselection of good responders has become increasingly evident. The purpose of our study is the establishment of a preselection of good responders for CDDP-based adjuvant chemotherapy. We investigated protein expressions comparing intensity between parent strains (H69 and PC14 lung cancer cultured cells) and resistant strains against CDDP using 2-dimensional polyacrylamide gel electrophoresis (2-DE). Immunohistochemically, we evaluated the relationship between protein expression associated with CDDP-resistance and the clinical effects of platinum-based postoperative adjuvant chemotherapy using 126 surgically-resected NCLC materials. We detected 2 kinds of polypeptides that changed expression levels on 2-DE gels. The analyses of the amino acid sequence showed that these polypeptides were reticulocalbin (RCN) and glutathione-Stransferase-p (GST-p). The 2-DE analysis showed decreased expression in RCN and overexpression in GST-p with the acquisition of CDDP-drug resistance. RCN-transfectant of H69 CDDPresistant strain showed intermediate sensitivity between the parent strain and the CDDP-resistant strain. RCN-positive cases showed a statistically significant better disease-free survival only in the cases receiving postoperative platinum-based adjuvant chemotherapy after curative resection (p 5 0.007). In addition, cases that were both RCN-positive and GST-p-negative showed a statistically significantly better outcome (p 5 0.0150). In the cases without postoperative adjuvant chemotherapy no relationship between the outcome and these expressions was seen. The evaluation of RCN and GST-p might provide valuable information concerning postoperatively therapeutic strategy from the standpoint of individualized postoperative therapy. ' 2005 Wiley-Liss, Inc.Key words: reticulocalbin; glutathione-S-transferase-p; cisplatin; individual therapy; non-small cell lung cancer Death due to lung cancer is still increasing in Japan and most Western countries, despite intensive application of various therapeutic strategies, and it is still the leading cause of cancer death in Japan. Though the opportunities of relatively early detection and treatment increase, still more than half of cases of primary lung cancer show advanced stage at the initial definitive diagnoses. Several years ago, we routinely carried out postoperative adjuvant chemotherapy using platinum (cisplatin [CDDP] or carboplatin) for patients with advanced stage non-small cell lung carcinoma (NSCLC) because distant metastasis occurred frequently after surgical treatment only. Clinically favorable outcome was not obtained, however, and the 5-year survival of Stage IIIA was approximately 25%, despite postoperative adjuvant chemotherapy. It had been believed that the efficacy of adjuvant chemotherapy in surgically resected lung cancer was controvers...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Identification of postoperative adjuvant chemotherapy responders in non‐small cell lung cancer by novel biomarker

Hirano

Kato

Maeda

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…7 The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis of these 5 large trials using individual patient data reported a significant benefit in overall survival with cisplatin-based AC (hazards ratio [HR], 0.89). 10 The Cancer and Leukemia Group B trial, which examined the effect of the combination of carboplatin and paclitaxel for patients with resected stage IB disease, initially reported significantly better survival rates with AC at 4 years of follow-up in 2004, 11 but subsequent analyses performed in 2006 did not reach statistical significance and were only suggestive of improved survival. 12 A post hoc subset analysis suggested that tumors measuring > 4 cm had a survival advantage with this doublet.…”

Section: Introductionmentioning

confidence: 99%

Use and impact of adjuvant chemotherapy in patients with resected non‐small cell lung cancer

Williams

Gajra

Ganti

et al. 2014

Cancer

View full text Add to dashboard Cite

BACKGROUND Despite clinical trials demonstrating improved survival with adjuvant chemotherapy (AC) for patients with American Joint Committee on Cancer stages I to III non‐small cell lung cancer (NSCLC), it is unclear whether this survival benefit extends to broader populations. The current study evaluated patterns of AC use and examined the impact of AC on survival. METHODS A retrospective analysis was conducted of patients in the Veterans Affairs Central Cancer Registry diagnosed with stages IB to IIIA NSCLC between 2001 and 2008. Descriptive statistics were used to examine patterns of AC use over an 8‐year time period. Cox proportional hazards regression analyses were used to estimate hazards ratios (HR) and 95% confidence intervals (95% CIs) to compare mortality risk among patients treated with and without AC. RESULTS Among 14,306 patients with stages IB to IIIA NSCLC, 4929 underwent surgery and 22% of these received AC. The percentages of patients diagnosed in 2001 through 2003, 2004 through 2005, and 2006 through 2008 receiving AC were 7.0%, 29.8%, and 29.5%, respectively. There was no survival benefit with AC noted for patients diagnosed between 2001 and 2003, but AC was associated with improved survival for the period between 2004 and 2005 (HR, 0.78; 95% CI, 0.67‐0.91) and 2006 through 2008 (HR, 0.79; 95% CI, 0.69‐0.91). Of those patients receiving AC, 89% received platinum‐doublet chemotherapy. Carboplatin remained the most common agent, although cisplatin use reached 43% in the period between 2006 and 2008. The HR for cisplatin relative to carboplatin was 0.96 (95% CI, 0.80‐1.15). CONCLUSIONS There was a significant increase in the use of AC between 2001 and 2008 and AC was associated with an improvement in overall survival. Cancer 2014;120:1939–1947. © 2014 American Cancer Society.

show abstract

“…Following surgery alone, the 5-year survival for patients with pathological stage IB, II and IIIA NSCLC is still disappointing at 60%, 40-50% and 25%, respectively (2). Adjuvant chemotherapy with platinum-based doublets has been shown to improve survival in wellconducted randomized trials (3)(4)(5)(6). The overall 5-year survival improvement in these studies ranged from 5 to 15% (3,4,6).…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590

Costa

Kocher

et al. 2007

Lung Cancer

View full text Add to dashboard Cite

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

Cited by 127 publications

References 0 publications

Identification of postoperative adjuvant chemotherapy responders in non‐small cell lung cancer by novel biomarker

Identification of postoperative adjuvant chemotherapy responders in non‐small cell lung cancer by novel biomarker

Use and impact of adjuvant chemotherapy in patients with resected non‐small cell lung cancer

Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590

Contact Info

Product

Resources

About